NBIO
Nascent Biotech, Inc. [NBIO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NBIO Stock Summary
Top 10 Correlated ETFs
NBIO
Top 10 Correlated Stocks
NBIO
In the News
NBIO Financial details
Company Rating
-
Market Cap
18.64M
Income
-2.09M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
29 Jun 2024
P/E
-6.97
Forward P/E
-
PEG
-0.07
P/S
-
P/B
-3358.67
P/C
-
P/FCF
-15.97
Quick Ratio
0.96
Current Ratio
0.99
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
1585.71%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-78.57%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-296%
ROE
323%
ROC
368.84%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0323-0.28
52W High
-
52W Low
-
RSI
26.11
Rel Volume
1.16
Avg Volume
75.27K
Volume
87K
Perf Week
-60%
Perf Month
-65.33%
Perf Quarter
-96.75%
Perf Half Y
-96.82%
-
-
-
-
Beta
-3.197
-
-
Volatility
0%, 0%
Prev Close
4%
Price
0.0026
Change
4%
Company Profile
- Volume Average 75.27K
- Market Capitalization 18.64M
- CEO Mr. Sean Carrick
- Headquarters Vero Beach,FL,US
- IPO Date 2009-12-03
-
Website
https://www.nascentbiotech.com 
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.
